Ozempic vs Mounjaro vs Zepbound: which preserves more muscle?

If you are choosing between GLP-1 medications, or comparing the one you are on against the alternatives, the muscle question is fair to ask. Some of the weight you lose on any of these drugs is lean tissue, not fat, and it is reasonable to wonder whether one option protects muscle better than another. The short answer is that the drugs differ in how much total weight they produce, but no head-to-head trial has cleanly settled which one preserves more muscle. Below is what the published data does and does not show.

First, the names

The brand names cause most of the confusion, so start there. Semaglutide is sold as Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). It activates a single receptor, GLP-1.¹ Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (weight management). It is a dual agonist, activating both the GLP-1 receptor and the GIP receptor.² So "Ozempic vs Wegovy" is the same molecule for two uses, and so is "Mounjaro vs Zepbound." The real comparison people mean is semaglutide versus tirzepatide.

Retatrutide comes up in the same conversation. It is a triple agonist that adds the glucagon receptor, and in a Phase 2 trial it produced even larger weight loss than the approved drugs.⁷ It is investigational: as of this writing it is not FDA-approved and is still in Phase 3 testing, so it is not an option you can choose today.⁸ We mention it only because you will see it in the news.

How much total weight each drug produces

The clearest difference between semaglutide and tirzepatide is the size of the weight loss. In its pivotal obesity trial, semaglutide 2.4 mg produced a mean weight reduction of about 14.9 percent over 68 weeks in STEP 1.³ Tirzepatide at its highest dose reached about 20.9 percent over 72 weeks in SURMOUNT-1.⁴ Retatrutide reached about 24.2 percent over 48 weeks in its Phase 2 trial, which is the reason it draws attention.⁷ These figures come from separate trials with different participants and durations, so treat them as ballpark magnitudes rather than a precise ranking, but the pattern is consistent: more receptors, more weight lost.

This matters for muscle in a way that is easy to miss. Even if two drugs lose the same fraction of weight as lean tissue, the drug that produces more total loss puts more absolute muscle on the line. That is the core reason the muscle question is not really about picking the "safer" drug.

What we actually know about body composition

The most useful composition data comes from the SURMOUNT-1 DXA substudy, which used dual-energy X-ray absorptiometry to separate fat from lean tissue in people taking tirzepatide. About 74 percent of the weight lost was fat and about 26 percent was lean mass.⁵ For semaglutide, a review calculated that lean mass accounted for roughly 45 percent of the weight lost in STEP 1, although the STEP 1 investigators emphasized that lean mass as a proportion of the shrinking body actually rose, because fat fell faster.⁶³ Across the broader GLP-1 trial literature, reviews place the lean-mass fraction of weight lost at roughly 15 to 40 percent.⁶

Read at face value, those two numbers, 26 percent for tirzepatide and about 45 percent for semaglutide, would suggest tirzepatide loses a smaller share of weight as muscle. But that reading is exactly the trap this article exists to flag.

Why the cross-trial comparison is not a clean winner

The 26 percent and the 45 percent do not come from the same study. They come from two different trials, run in different populations, using different body-composition methods and different ways of expressing the result. DXA itself measures "lean mass," which includes water and organ tissue, not just contractile muscle, and small differences in method can move the percentage meaningfully. Comparing a number from SURMOUNT-1 against a number from STEP 1 is not the same as measuring both drugs the same way in the same people. No trial has done that head to head. So the tidy conclusion that "tirzepatide preserves more muscle" is not supported; it is an artifact of stacking two separate measurements next to each other.

There is also evidence pointing the other direction. A large routine-care analysis of paired body-composition scans reported that tirzepatide users lost more lean mass than semaglutide users at every time point checked over 12 months, with the gap widening over treatment.⁹ That analysis is a preprint and has not been peer reviewed, so it should not be treated as settled. But it is a real signal that runs opposite to the cross-trial DXA percentages, which is the clearest sign that the question is genuinely unresolved.

The conclusion that actually holds

Here is what survives an honest look at the data. The bigger the total weight loss, the more absolute muscle you stand to lose, so the muscle-preserving work becomes more important on the stronger drug, not less. Whichever medication you and your clinician choose, the countermeasure is the same, and it is well supported.

Resistance training. In a meta-analysis of older adults losing weight through caloric restriction, adding resistance training offset about 93.5 percent of the lean-mass loss that dieting alone would have caused, a difference of roughly 0.82 kg of preserved lean tissue.¹⁰ You do not need to be an athlete; you need to load your major muscle groups a few times a week and progress over time.

Protein. A dose-response meta-analysis found that protein intake improved resistance-training gains up to a breakpoint near 1.6 grams per kilogram of body weight per day, beyond which more protein added little.¹¹ On a strongly suppressed appetite, which is exactly what tirzepatide and semaglutide produce, hitting that target takes a deliberate plan rather than good intentions.

One caution worth keeping in view: a drop on a DXA scan is an imperfect stand-in for strength, and short-term GLP-1 trials often show preserved grip strength even as lean mass falls. But longer-term research in older adults reports reductions in strength and function, so the safe move is to track what you can actually lift over time rather than trusting a single scan.¹²

Why muscle is worth defending on either drug

The reason to protect muscle now is what tends to happen later. In the STEP 1 trial extension, participants who came off semaglutide regained about two-thirds of their lost weight within a year: average net weight loss fell from 17.3 percent at the end of treatment to 5.6 percent one year after stopping.¹³ Muscle is the reserve you carry into that phase, and it is harder to rebuild than fat. Dedicated trials such as LEAN-PREP are now enrolling to test resistance exercise and protein specifically during semaglutide and tirzepatide therapy, so this is an active question, not a niche one.¹⁴

The bottom line

Semaglutide and tirzepatide differ clearly in how much weight they produce, and less clearly in how much of that weight is muscle. The best available numbers hint that tirzepatide loses a smaller share as lean mass, a routine-care preprint hints the opposite, and neither is a head-to-head measurement, so no honest source can name a winner. The choice of medication belongs to you and your clinician and should turn on efficacy, side effects, coverage, and your health history. The muscle outcome, by contrast, is largely in your hands: resistance training and enough protein protect lean mass on any of these drugs, and they matter more the more weight you lose.

Frequently asked